The post David Sinclair: Aging can be reversed, gene therapy is key to rejuvenation, and we may live into the twenty-second century appeared on BitcoinEthereumNewsThe post David Sinclair: Aging can be reversed, gene therapy is key to rejuvenation, and we may live into the twenty-second century appeared on BitcoinEthereumNews

David Sinclair: Aging can be reversed, gene therapy is key to rejuvenation, and we may live into the twenty-second century

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com


Age reversal research could redefine human health, with trials soon to begin on reversing blindness.

Key takeaways

  • Aging is not an inevitable process and can potentially be reversed.
  • People may live into the twenty-second century with the right practices.
  • Reversing aging could lead to cures for diseases like Alzheimer’s, cancer, and heart disease.
  • Understanding and reversing aging could have the biggest impact on human health in history.
  • Human trials for age reversal technology are set to begin soon, marking a significant milestone.
  • The eye is chosen for age reversal studies due to its safety as an enclosed system.
  • Introducing and activating specific genes can rejuvenate the optic nerve.
  • We can safely reset the age of cells by about 75%.
  • The biology of aging is understood, and the information theory of aging remains unchallenged.
  • Aging is a universal process that can potentially be reversed, changing our understanding of health.
  • Age reversal research could transform human history.
  • Gene therapy plays a crucial role in reversing aging processes in specific tissues.
  • The strategic choice of the eye for initial trials highlights safety considerations.
  • Advances in longevity research suggest a transformative future for human life expectancy.
  • The potential benefits of aging research underscore its importance in the field of health.

Guest intro

David A. Sinclair, A.O., Ph.D. is a Professor of Genetics in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for Biology of Aging Research. He co-discovered a cause of aging in yeast and the role of Sir2 in epigenetic changes during his postdoctoral work at MIT. His lab demonstrated that aging can be reversed in animal models to cure blindness.

Why aging is not inevitable

  • — David Sinclair

  • Sinclair challenges the belief that aging is a natural and acceptable process.
  • — David Sinclair

  • Reversing aging could cure major diseases like Alzheimer’s and cancer.
  • — David Sinclair

  • Understanding aging could have the biggest impact on human health in history.
  • — David Sinclair

  • Aging is a universal process that can be potentially reversed, fundamentally changing health perspectives.
  • — David Sinclair

The potential for living into the twenty-second century

  • People may live into the twenty-second century with the right practices.
  • — David Sinclair

  • Advances in longevity research suggest a transformative future for human life expectancy.
  • Human trials for age reversal technology are set to begin soon, marking a significant milestone.
  • — David Sinclair

  • Age reversal research could transform human history.
  • — David Sinclair

  • The potential benefits of aging research underscore its importance in the field of health.

The role of gene therapy in age reversal

  • The eye is chosen for age reversal studies due to its safety as an enclosed system.
  • — David Sinclair

  • Introducing and activating specific genes can rejuvenate the optic nerve.
  • — David Sinclair

  • Gene therapy plays a crucial role in reversing aging processes in specific tissues.
  • The strategic choice of the eye for initial trials highlights safety considerations.
  • — David Sinclair

  • Advances in gene therapy could lead to significant breakthroughs in age-related conditions.

Resetting cellular age

  • We can safely reset the age of cells by about 75%.
  • — David Sinclair

  • This process does not regress cells back to zero, which is beneficial.
  • — David Sinclair

  • Understanding cellular age resetting has potential applications in medicine.
  • This claim presents a significant advancement in cellular aging research.
  • Cellular age resetting is central to Sinclair’s research and its potential impact on health.

The information theory of aging

  • The biology of aging is understood, and the information theory of aging remains unchallenged.
  • — David Sinclair

  • This theory provides insight into the scientific foundation of Sinclair’s work.
  • Understanding this theory is crucial for grasping the potential to reverse aging.
  • The information theory of aging underpins Sinclair’s confidence in reversing aging.
  • This theory suggests a transformative approach to understanding biological aging.
  • The potential to reverse aging is grounded in a solid scientific framework.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Age reversal research could redefine human health, with trials soon to begin on reversing blindness.

Key takeaways

  • Aging is not an inevitable process and can potentially be reversed.
  • People may live into the twenty-second century with the right practices.
  • Reversing aging could lead to cures for diseases like Alzheimer’s, cancer, and heart disease.
  • Understanding and reversing aging could have the biggest impact on human health in history.
  • Human trials for age reversal technology are set to begin soon, marking a significant milestone.
  • The eye is chosen for age reversal studies due to its safety as an enclosed system.
  • Introducing and activating specific genes can rejuvenate the optic nerve.
  • We can safely reset the age of cells by about 75%.
  • The biology of aging is understood, and the information theory of aging remains unchallenged.
  • Aging is a universal process that can potentially be reversed, changing our understanding of health.
  • Age reversal research could transform human history.
  • Gene therapy plays a crucial role in reversing aging processes in specific tissues.
  • The strategic choice of the eye for initial trials highlights safety considerations.
  • Advances in longevity research suggest a transformative future for human life expectancy.
  • The potential benefits of aging research underscore its importance in the field of health.

Guest intro

David A. Sinclair, A.O., Ph.D. is a Professor of Genetics in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for Biology of Aging Research. He co-discovered a cause of aging in yeast and the role of Sir2 in epigenetic changes during his postdoctoral work at MIT. His lab demonstrated that aging can be reversed in animal models to cure blindness.

Why aging is not inevitable

  • — David Sinclair

  • Sinclair challenges the belief that aging is a natural and acceptable process.
  • — David Sinclair

  • Reversing aging could cure major diseases like Alzheimer’s and cancer.
  • — David Sinclair

  • Understanding aging could have the biggest impact on human health in history.
  • — David Sinclair

  • Aging is a universal process that can be potentially reversed, fundamentally changing health perspectives.
  • — David Sinclair

The potential for living into the twenty-second century

  • People may live into the twenty-second century with the right practices.
  • — David Sinclair

  • Advances in longevity research suggest a transformative future for human life expectancy.
  • Human trials for age reversal technology are set to begin soon, marking a significant milestone.
  • — David Sinclair

  • Age reversal research could transform human history.
  • — David Sinclair

  • The potential benefits of aging research underscore its importance in the field of health.

The role of gene therapy in age reversal

  • The eye is chosen for age reversal studies due to its safety as an enclosed system.
  • — David Sinclair

  • Introducing and activating specific genes can rejuvenate the optic nerve.
  • — David Sinclair

  • Gene therapy plays a crucial role in reversing aging processes in specific tissues.
  • The strategic choice of the eye for initial trials highlights safety considerations.
  • — David Sinclair

  • Advances in gene therapy could lead to significant breakthroughs in age-related conditions.

Resetting cellular age

  • We can safely reset the age of cells by about 75%.
  • — David Sinclair

  • This process does not regress cells back to zero, which is beneficial.
  • — David Sinclair

  • Understanding cellular age resetting has potential applications in medicine.
  • This claim presents a significant advancement in cellular aging research.
  • Cellular age resetting is central to Sinclair’s research and its potential impact on health.

The information theory of aging

  • The biology of aging is understood, and the information theory of aging remains unchallenged.
  • — David Sinclair

  • This theory provides insight into the scientific foundation of Sinclair’s work.
  • Understanding this theory is crucial for grasping the potential to reverse aging.
  • The information theory of aging underpins Sinclair’s confidence in reversing aging.
  • This theory suggests a transformative approach to understanding biological aging.
  • The potential to reverse aging is grounded in a solid scientific framework.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Loading more articles…

You’ve reached the end


Add us on Google

`;
}

function createMobileArticle(article) {
const displayDate = getDisplayDate(article);
const editorSlug = article.editor ? article.editor.toLowerCase().replace(/\s+/g, ‘-‘) : ”;
const captionHtml = article.imageCaption ? `

${article.imageCaption}

` : ”;
const authorHtml = article.isPressRelease ? ” : `
`;

return `


${captionHtml}

${article.subheadline ? `

${article.subheadline}

` : ”}

${createSocialShare()}

${authorHtml}
${displayDate}

${article.content}

${article.isPressRelease ? ” : article.isSponsored ? `

Disclosure: This is sponsored content. It does not represent Crypto Briefing’s editorial views. For more information, see our Editorial Policy.

` : `

Disclosure: This article was edited by ${article.editor}. For more information on how we create and review content, see our Editorial Policy.

`}

`;
}

function createDesktopArticle(article, sidebarAdHtml) {
const editorSlug = article.editor ? article.editor.toLowerCase().replace(/\s+/g, ‘-‘) : ”;
const displayDate = getDisplayDate(article);
const captionHtml = article.imageCaption ? `

${article.imageCaption}

` : ”;
const categoriesHtml = article.categories.map((cat, i) => {
const separator = i < article.categories.length – 1 ? ‘|‘ : ”;
return `${cat}${separator}`;
}).join(”);
const desktopAuthorHtml = article.isPressRelease ? ” : `
`;

return `

${categoriesHtml}

${article.subheadline ? `

${article.subheadline}

` : ”}

${desktopAuthorHtml}
${displayDate}
${createSocialShare()}

${captionHtml}

${article.content}
${article.isPressRelease ? ” : article.isSponsored ? `
Disclosure: This is sponsored content. It does not represent Crypto Briefing’s editorial views. For more information, see our Editorial Policy.

` : `

Disclosure: This article was edited by ${article.editor}. For more information on how we create and review content, see our Editorial Policy.

`}

`;
}

function loadMoreArticles() {
if (isLoading || !hasMore) return;

isLoading = true;
loadingText.classList.remove(‘hidden’);

// Build form data for AJAX request
const formData = new FormData();
formData.append(‘action’, ‘cb_lovable_load_more’);
formData.append(‘current_post_id’, lastLoadedPostId);
formData.append(‘primary_cat_id’, primaryCatId);
formData.append(‘before_date’, lastLoadedDate);
formData.append(‘loaded_ids’, loadedPostIds.join(‘,’));

fetch(ajaxUrl, {
method: ‘POST’,
body: formData
})
.then(response => response.json())
.then(data => {
isLoading = false;
loadingText.classList.add(‘hidden’);

if (data.success && data.has_more && data.article) {
const article = data.article;
const sidebarAdHtml = data.sidebar_ad_html || ”;

// Check for duplicates
if (loadedPostIds.includes(article.id)) {
console.log(‘Duplicate article detected, skipping:’, article.id);
// Update pagination vars and try again
lastLoadedDate = article.publishDate;
loadMoreArticles();
return;
}

// Add to mobile container
mobileContainer.insertAdjacentHTML(‘beforeend’, createMobileArticle(article));

// Add to desktop container with fresh ad HTML
desktopContainer.insertAdjacentHTML(‘beforeend’, createDesktopArticle(article, sidebarAdHtml));

// Update tracking variables
loadedPostIds.push(article.id);
lastLoadedPostId = article.id;
lastLoadedDate = article.publishDate;

// Execute any inline scripts in the new content (for ads)
const newArticle = desktopContainer.querySelector(`article[data-article-id=”${article.id}”]`);
if (newArticle) {
const scripts = newArticle.querySelectorAll(‘script’);
scripts.forEach(script => {
const newScript = document.createElement(‘script’);
if (script.src) {
newScript.src = script.src;
} else {
newScript.textContent = script.textContent;
}
document.body.appendChild(newScript);
});
}

// Trigger Ad Inserter if available
if (typeof ai_check_and_insert_block === ‘function’) {
ai_check_and_insert_block();
}

// Trigger Google Publisher Tag refresh if available
if (typeof googletag !== ‘undefined’ && googletag.pubads) {
googletag.cmd.push(function() {
googletag.pubads().refresh();
});
}

} else if (data.success && !data.has_more) {
hasMore = false;
endText.classList.remove(‘hidden’);
} else if (!data.success) {
console.error(‘AJAX error:’, data.error);
hasMore = false;
endText.textContent=”Error loading more articles”;
endText.classList.remove(‘hidden’);
}
})
.catch(error => {
console.error(‘Fetch error:’, error);
isLoading = false;
loadingText.classList.add(‘hidden’);
hasMore = false;
endText.textContent=”Error loading more articles”;
endText.classList.remove(‘hidden’);
});
}

// Set up IntersectionObserver
const observer = new IntersectionObserver(function(entries) {
if (entries[0].isIntersecting) {
loadMoreArticles();
}
}, { threshold: 0.1 });

observer.observe(loadingTrigger);
})();

© Decentral Media and Crypto Briefing® 2026.

Source: https://cryptobriefing.com/david-sinclair-aging-can-be-reversed-gene-therapy-is-key-to-rejuvenation-and-we-may-live-into-the-twenty-second-century-the-diary-of-a-ceo/

Market Opportunity
SOON Logo
SOON Price(SOON)
$0.1224
$0.1224$0.1224
-2.70%
USD
SOON (SOON) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

BTC supply on centralized exchanges is at a 7-year low

BTC supply on centralized exchanges is at a 7-year low

PANews reported on September 18th that crypto analyst The DeFi Investor wrote on the X platform: "The supply of BTC on centralized exchanges is at its lowest level in seven years. The scale of funds invested by institutions in purchasing Bitcoin in this cycle is incredible."
Share
PANews2025/09/18 09:53
Breaking: CME Group Unveils Solana and XRP Options

Breaking: CME Group Unveils Solana and XRP Options

CME Group launches Solana and XRP options, expanding crypto offerings. SEC delays Solana and XRP ETF approvals, market awaits clarity. Strong institutional demand drives CME’s launch of crypto options contracts. In a bold move to broaden its cryptocurrency offerings, CME Group has officially launched options on Solana (SOL) and XRP futures. Available since October 13, 2025, these options will allow traders to hedge and manage exposure to two of the most widely traded digital assets in the market. The new contracts come in both full-size and micro-size formats, with expiration options available daily, monthly, and quarterly, providing flexibility for a diverse range of market participants. This expansion aligns with the rising demand for innovative products in the crypto space. Giovanni Vicioso, CME Group’s Global Head of Cryptocurrency Products, noted that the new options offer increased flexibility for traders, from institutions to active individual investors. The growing liquidity in Solana and XRP futures has made the introduction of these options a timely move to meet the needs of an expanding market. Also Read: Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple! Rapid Growth in Solana and XRP Futures Trading CME Group’s decision to roll out options on Solana and XRP futures follows the substantial growth in these futures products. Since the launch of Solana futures in March 2025, more than 540,000 contracts, totaling $22.3 billion in notional value, have been traded. In August 2025, Solana futures set new records, with an average daily volume (ADV) of 9,000 contracts valued at $437.4 million. The average daily open interest (ADOI) hit 12,500 contracts, worth $895 million. Similarly, XRP futures, which launched in May 2025, have seen significant adoption, with over 370,000 contracts traded, totaling $16.2 billion. XRP futures also set records in August 2025, with an ADV of 6,600 contracts valued at $385 million and a record ADOI of 9,300 contracts, worth $942 million. Institutional Demand for Advanced Hedging Tools CME Group’s expansion into options is a direct response to growing institutional interest in sophisticated cryptocurrency products. Roman Makarov from Cumberland Options Trading at DRW highlighted the market demand for more varied crypto products, enabling more advanced risk management strategies. Joshua Lim from FalconX also noted that the new options products meet the increasing need for institutional hedging tools for assets like Solana and XRP, further cementing their role in the digital asset space. The launch of options on Solana and XRP futures marks another step toward the maturation of the cryptocurrency market, providing a broader range of tools for managing digital asset exposure. SEC’s Delay on Solana and XRP ETF Approvals While CME Group expands its offerings, the broader market is also watching the progress of Solana and XRP exchange-traded funds (ETFs). The U.S. Securities and Exchange Commission (SEC) has delayed its decisions on multiple crypto-related ETF filings, including those for Solana and XRP. Despite the delay, analysts anticipate approval may be on the horizon. This week, REX Shares and Osprey Funds are expected to launch an XRP ETF that will hold XRP directly and allocate at least 40% of its assets to other XRP-related ETFs. Despite the delays, some analysts believe that approval could come soon, fueling further interest in these assets. The delay by the SEC has left many crypto investors awaiting clarity, but approval of these ETFs could fuel further momentum in the Solana and XRP futures markets. Also Read: Tether CEO Breaks Silence on $117,000 Bitcoin Price – Market Reacts! The post Breaking: CME Group Unveils Solana and XRP Options appeared first on 36Crypto.
Share
Coinstats2025/09/18 02:35
Why Fintech Platforms Are Growing Faster Than Traditional Banks

Why Fintech Platforms Are Growing Faster Than Traditional Banks

Fintech platforms are outpacing traditional banks in growth across nearly every measurable dimension. Customer acquisition rates, revenue growth, geographic expansion
Share
Techbullion2026/03/24 07:58